RADIOLABELLED ALPHA-V BETA-3 AND/OR ALPHA-V BETA-5 INTEGRINS ANTAGONIST FOR USE AS THERAGNOSTIC AGENT

The present disclosure relates to αvβ3 and/or αvβ5 integrins antagonist radiopharmaceuticals and their use in a theragnostic approach for selection and therapy of human subjects with tumors overexpressing αvβ3 and/or αvβ5 integrins. In particular, the present disclosure relates to a pharmaceutical c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ROSSETTO, Mattia, WEGENER, Antje, MAGRI, Alessandro, DE CARLI, Francesco, BARENGO, Daniela, MUZIO, Valeria, CAMERON, John Scott, BARDINI, Paola
Format:	Patent
Sprache:	eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present disclosure relates to αvβ3 and/or αvβ5 integrins antagonist radiopharmaceuticals and their use in a theragnostic approach for selection and therapy of human subjects with tumors overexpressing αvβ3 and/or αvβ5 integrins. In particular, the present disclosure relates to a pharmaceutical composition of αv 177Lu radiolabeled αvβ3 and/or αvβ5 integrins antagonist, for use in treating tumors overexpressing αvβ3 and/or αvβ5 integrins in a human subject eligible for said treatment, wherein said subject has been selected for the treatment by PET/CT or PET/MRI or SPECT/CT or SPECT/MRI imaging with the same αvβ3 and/or αvβ5 integrins antagonist but with 68-Ga as radiometal for use as imaging agent.